Baker Heart and Diabetes Institute looking at new ways of treating heart disease in people with diabetes 15 December 2017 Heart disease is one of the major complications associated with diabetes, however some of the first line treatments used to reduce a person’s risk of heart disease, don’t work as well in people with diabetes. This problem is a major focus of research being conducted by Dr Brian Drew and his colleagues at the Baker Heart and Diabetes Institute and supported by the Diabetes Australia Research Trust. Diabetes, Dr Drew says, often leads to an increase in ‘bad’ cholesterol levels which contributes to the risk for heart disease in these people. “The primary drugs used to lower cholesterol levels and reduce cardiovascular risk are statins. These drugs are generally effective in people who don’t have diabetes, but they are far less effective in people with diabetes,” he says. “This is a problem because people with diabetes are three to four times more likely to develop cardiovascular disease than people without diabetes. “What we’re working towards is a new drug target that would be effective in reducing bad cholesterol levels in people with diabetes.” Using high tech genetic screening, Dr Drew’s team has identified a protein which they call DDL1, which could play a role in regulating cholesterol levels differently to the way way current medications such as statins, work. “We want to understand if this protein, DDL1, can alter cholesterol levels and we will be testing this in preclinical models,” he says. “It’s never been associated with lowering cholesterol levels before so we are breaking new ground. “We hope that any new therapy could also work for people who experience some of the major side effects of statins like muscle soreness.”
Media releases 18 November 2026 Foundayo approval a welcome addition to GLP-1 treatment options Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading